metricas
covid
Annals of Hepatology Utility of the CLIF-C AD score to assess readmission in patients with acute deco...
Journal Information
Vol. 30. Issue S1.
Abstracts Asociación Mexicana de Hepatología (AMH) 2024
(April 2025)
Vol. 30. Issue S1.
Abstracts Asociación Mexicana de Hepatología (AMH) 2024
(April 2025)
Full text access
Utility of the CLIF-C AD score to assess readmission in patients with acute decompensation of non-ACLF cirrhosis.
Visits
382
Cristian A. Oviedo-Garza, Alejandro Peña-Montes, María R. Herrero Maceda, Scherezada M. Loza-Mejia
Gastroenterology and Hepatology, Hospital Juárez, México
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Special issue
This article is part of special issue:
Vol. 30. Issue S1

Abstracts Asociación Mexicana de Hepatología (AMH) 2024

More info
Introduction and Objectives

Patients with cirrhosis who require hospitalization due to acute decompensation (ascites, digestive bleeding, hepatic encephalopathy, among others), have a variable adverse prognosis, depending on whether they have acute-on-chronic liver failure (ACLF), the CLIF-C AD test allows to identify the risk of readmission, development of ACLF and mortality.

Materials and Patients

A cross-sectional study was carried out between October 2023 and May 2024. The CLIF-C AD test was calculated in patients with decompensated cirrhosis. The results were analyzed using descriptive statistics, frequency analysis, and percentages. Group comparison analysis was performed with Student's T and chi square as appropriate, to determine the sensitivity and specificity of this test, and a ROC curve was performed; Likewise, Kaplan Meyer curves of 2 groups were used according to the CLIF-C AD categorized as 62 or less and greater than 62; having a significant value of p:0.005; The analysis was performed with the statistical program SPSS version 25.

Results

There were 40 patients; 32 men and 8 women. Cirrhosis etiology: alcohol 30 patients (75%), MASLD 8 patients (20%), autoimmune hepatitis 2 patients (5%). Cause of decompensation: Upper digestive bleeding in 19 patients (47.5%), urinary infection in 8 patients (20%), tense ascites in 4 patients (10%), spontaneous bacterial peritonitis in 3 patients (7.5%). Findings on admission: ascites 27 patients (67.5%), hepatic encephalopathy 27 patients (67.5%), shock 18 patients (45%). The CLIF-C-AD score with a median of 68 IQR (52-73). Readmission 35 patients (87.5%); The cause of readmission was hepatic encephalopathy in 17 patients (42.5%), upper digestive bleeding in 10 patients (25%), and acute kidney injury in 3 patients (7.5%). Using Student's T, the CLIF-C AD score is determined for those who were readmitted with a mean of 66 and for those who were not readmitted with a mean of 41 (p<0.001). In the ROC curve, the area under the curve was found to be 0.950 with 95% CI (0.890-1.000) p=0.001, sensitivity 77%, specificity 100%, with a Youden point of 62 points; Therefore, it is categorized into 2 groups based on this score for a cumulative incidence of readmission by Kaplan Meier curve, showing a difference between the groups with a Log Rang test of 0.005.

Conclusions

The CLIF-C AD score is a practical, adequate, and useful tool to determine the outcome of decompensated cirrhotic patients, which will allow the identification of high-risk patients and the implementation of close follow-up strategies and timely therapeutic adjustment and avoid adverse outcomes. More studies are required and increased sample size.

Full Text

Ethical statement: This protocol was registered and approved by the ethics committee. Patients’ identities are protected. Consent was obtained.

Declaration of interests: None.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Download PDF
Article options
Tools